aTYR PHARMA INC

aTyr Pharma Advances Novel Anti-Fibrotic Therapy ATYR0101 for Pulmonary Fibrosis

9 days ago

• aTyr Pharma has advanced ATYR0101, a fusion protein that targets LTBP-1, to IND candidate stage for pulmonary fibrosis with potential to reverse fibrosis rather than just slow progression. • Preclinical data demonstrates ATYR0101 induces myofibroblast cell death through a unique mechanism, offering a differentiated approach to treating fibrotic diseases. • The company plans to present ATYR0101 at the American Thoracic Society 2025 Respiratory Innovation Summit and anticipates filing an IND application in the second half of 2026.

Science Translational Medicine Validates Efzofitimod's Novel Mechanism for Treating Lung Inflammation

2 months ago

• aTyr Pharma's efzofitimod demonstrates a unique anti-inflammatory mechanism targeting the neuropilin-2 receptor on macrophages, as validated in a peer-reviewed Science Translational Medicine publication. • The first-in-class immunomodulator, derived from histidyl-tRNA synthetase, downregulates inflammatory pathways and disrupts the cycle of chronic inflammation and fibrosis in lung tissue. • Efzofitimod is currently in Phase 3 trials for pulmonary sarcoidosis and Phase 2 studies for systemic sclerosis-related interstitial lung disease, with orphan drug and Fast Track designations.

aTyr Pharma's Efzofitimod Shows Continued Promise in Phase 3 Pulmonary Sarcoidosis Trial

5 months ago

• aTyr Pharma's efzofitimod maintains a positive safety profile in the Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis, according to an independent DSMB review. • The EFZO-FIT™ trial, involving 268 patients, assesses efzofitimod's efficacy in reducing corticosteroid use and improving lung function in pulmonary sarcoidosis. • aTyr Pharma will present three posters on efzofitimod and pulmonary sarcoidosis at the American Thoracic Society (ATS) 2025 International Conference. • Topline data from the Phase 3 EFZO-FIT study is anticipated in the third quarter of 2025, potentially offering a new treatment option for this chronic condition.